Stonepine Capital Management buys $3,819,450 stake in Recro Pharma Inc (REPH)

Recro Pharma Inc (REPH) : Stonepine Capital Management scooped up 191,796 additional shares in Recro Pharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 428,670 shares of Recro Pharma Inc which is valued at $3,819,450.Recro Pharma Inc makes up approximately 4.08% of Stonepine Capital Management’s portfolio.

Other Hedge Funds, Including , Blackrock Institutional Trust Company N.a. boosted its stake in REPH in the latest quarter, The investment management firm added 11,682 additional shares and now holds a total of 49,947 shares of Recro Pharma Inc which is valued at $445,028.Acrospire Investment Management boosted its stake in REPH in the latest quarter, The investment management firm added 6,310 additional shares and now holds a total of 8,215 shares of Recro Pharma Inc which is valued at $80,507. Recro Pharma Inc makes up approx 0.06% of Acrospire Investment Management’s portfolio. Mufg Americas Holdings Corp added REPH to its portfolio by purchasing 570 company shares during the most recent quarter which is valued at $5,096.

Recro Pharma Inc closed down -0.05 points or -0.59% at $8.48 with 36,019 shares getting traded on Friday. Post opening the session at $8.59, the shares hit an intraday low of $8.36 and an intraday high of $8.6 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Recro Pharma Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies) especially of the lower extremities which can occur in diabetic patients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *